Sanofi Pasteur, the vaccines division of Sanofi, has launched its paediatric pentavalent vaccine, 'Shan5', developed and manufactured by its affiliate Shantha in India.
Sanofi�s Dengue Vaccine Meets Goal in Clinical Trial
French pharmaceutical giant Sanofi revealed that its experimental dengue vaccine has managed to meet its primary goal.
French pharmaceutical giant Sanofi revealed that its experimental dengue vaccine has managed to meet its primary goal.
Further, the prequalification helps Shan5 secure the supply of pentavalent combination vaccines in over 50 low-income countries. It adds to the current list of four vaccines that Shantha manufactures that includes Shanchol–the innovative cholera vaccine.
“A significant number of babies born every year in India do not have access to modern vaccination programmes. The launch of Shan5 in India means that 27 million babies born annually in India will have access to vaccination, to protect them from 5 potentially deadly diseases. By launching Shan5, Shantha will be contributing to filling this immunization gap for the benefit of babies and their parents", said Dr.Harish Iyer, CEO-Shantha.
Sanofi Attains Targets Despite Profit Slip, Shares Plunge
French drugmaking group Sanofi has reported that net profit slipped in the third quarter but that its main treatments were doing well and research for new drugs looked promising.
French drugmaking group Sanofi has reported that net profit slipped in the third quarter but that its main treatments were doing well and research for new drugs looked promising.
Shantha is a biotechnology pioneer from the emerging countries, founded by Dr. K I Varaprasad Reddy in 1993 in Hyderabad, India.
Shantha and Sanofi Pasteur are also developing a new pediatric combination vaccine based on Shan5 that will incorporate Sanofi Pasteur’s Inactivated Polio Vaccine in order to secure polio eradication.
Advertisement
Ready: First Semi-synthetic Malaria Drugs from French Drugmaker Sanofi
French pharmaceutical giant Sanofi announced the delivery of the first anti-malaria drugs that use a semi-synthetic version of their key ingredient Artemisinin to millions of patients in Africa.
French pharmaceutical giant Sanofi announced the delivery of the first anti-malaria drugs that use a semi-synthetic version of their key ingredient Artemisinin to millions of patients in Africa.
Source-Medindia
FDA Asks Sanofi to Assess Potential Neurocognitive Side Effects of Experimental Cholesterol Drug
Sanofi confirmed that it has been asked by the USFDA to assess the potential neurocognitive side effects of its experimental cholesterol drug.
Sanofi confirmed that it has been asked by the USFDA to assess the potential neurocognitive side effects of its experimental cholesterol drug.
